Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

United Therapeutics Scores $45 Million To Develop Novel Virology Treatments

This article was originally published in The Pink Sheet Daily

Executive Summary

United Therapeutics Corp. gets a $45 million tranched grant from the U.S. National Institute of Allergy and Infectious Disease to develop broad-spectrum compounds against influenza and Dengue.

You may also be interested in...



Visterra Strikes Deal With Pfizer, Presents Strong Data For Flu Drug

The start-up supplied few details about its arrangement with its Big Pharma partner, but receives cash as it prepares to take a promising influenza therapy into the clinic.

Despite Latest Oral Remodulin Phase III Flop, UTHR Says It Still Has Enough Data For FDA

The company tells skeptical analysts it will pursue a limited monotherapy label based on a single positive Phase III study in the wake of a second combination trial failure.

Vaccine Upstart Inviragen Aims to Capture Dengue Market

Six-year-old Inviragen may be the biotech of the future.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel